Although it is true that the medial technology industry nowadays gets a lot of attention from investors, but it has not translated to a lot of joy for investors in Sigyn Therapeutics Inc (OTCMKTS:SIGY).
Trading Data
On Friday, SIGY stock ended flat at $0.4590 with more than 20 shares traded, compared to its average volume of 1.02k shares. The stock has moved within a range of $0.4590 – 0.4590 after opening trading at $0.4595.
Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines
The company, which is involved in development of treatments meant for pathogen related ailments that bring about sepsis, has seen its stock go on a downward spiral over the past month. During the course of that period, the stock has gone down by as much as 40% and in this situation, it may be a good move for investors to take a closer look at some of the recent events.
Last week on December 17 the company was in the news after the company’s Chief Executive Officer and Chairman, Jim Joyce, released a note. He provided details with regards to the implications of the latest surge in COVID 19 cases related to the Omicron variant on the wider operations of the company.
In this context, Joyce noted that the first therapies that had been approved by the regulators had not actually been vaccines or drugs for the treatment of the disease. Despite the fall in the stock price, it might be a good move to keep the Sigyn stock in your watch lists at this point.
